| Previous Close | 1.1200 |
| Open | 1.1200 |
| Bid | 1.1100 x 0 |
| Ask | 1.1300 x 0 |
| Day's Range | 1.1100 - 1.1300 |
| 52 Week Range | 0.8600 - 4.0500 |
| Volume | 8,305 |
| Avg. Volume | 93,489 |
| Market Cap | 76.275M |
| Beta (5Y Monthly) | 2.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2650 |
| Earnings Date | Aug. 04, 2021 - Aug. 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.63 |
- Newsfile
Largest Real-World Registry Supporting Neovasc Reducer(TM) Safety and Efficacy Outcomes Published in International Journal of Cardiology
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 18, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the publication of an article entitled, "Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE Study" in the International Journal of Cardiology.The article, authored by Francesco Ponticelli, M.D., Maria Cecilia Hospital, Cotignola, Italy, describes long-term outcomes of p
- GlobeNewswire
Largest Real-World Registry Supporting Neovasc Reducer™ Safety and Efficacy Outcomes Published in International Journal of Cardiology
VANCOUVER and MINNEAPOLIS, June 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE Study” in the International Journal of Cardiology. The article, authored by Francesco Ponticelli, M.D., Maria Cecilia Hospital, Cotignola, Italy, describes long-term outcomes of patients sufferin
- Simply Wall St.
Neovasc (TSE:NVCN) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
